All In Biotech

Drug Trial Radar · NCT02271217

A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets.

This is a Multi-center, Double-blind, Three Arm, Parallel Group, Placebo-controlled, Randomized Study Designed to Evaluate the Efficacy, Safety and Tolerability of Dalfampridine.

Last checked: Nov 20, 2026Latest source record: Jun 7, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 377 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

377

Actual

Start

Dec 2014

Primary completion

Sep 2016

Study completion Oct 2016

Sponsor

Lead sponsor
Acorda TherapeuticsIndustry
Sponsor type
Industry
First posted
Oct 22, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to determine the effect of two dose strengths of dalfampridine-Extended Release (ER) tablets, taken twice daily for 12 weeks, on stable walking deficits in subjects with post-ischemic stroke.

Conditions

  • Post-Ischemic Stroke

Interventions

  • PlaceboDrug

  • dalfampridine-ER 7.5mgDrug

  • dalfampridine-ER 10mgDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Subjects Who Show at Least a 20% Improvement on the Two Minute Walk Test (2MinWT) at Week 12Time frame: Week 12

Locations

74 sites in 2 countries. Site status is shown where the registry gives one.

  • Acorda Site #117

    Gilbert, Arizona

  • Acorda Site #109

    Berkeley, California

  • Acorda Site #138

    Long Beach, California

  • Acorda Site #105

    Newport Beach, California

  • Acorda Site #170

    Oceanside, California

  • Acorda Site #142

    Pasadena, California

  • Acorda Site #153

    Sacramento, California

  • Acorda Site #151

    San Diego, California

  • Acorda Site #163

    San Diego, California

  • Acorda Site #124

    Colorado Springs, Colorado

  • Acorda Site #110

    Danbury, Connecticut

  • Acorda Site #149

    Fairfield, Connecticut

  • Acorda Site #130

    Stamford, Connecticut

  • Acorda Site #115

    Atlantis, Florida

  • Acorda Site #119

    Deerfield Beach, Florida

  • Acorda Site #147

    Gainesville, Florida

  • Acorda Site #128

    Hialeah, Florida

  • Acorda Site #143

    Jacksonville, Florida

  • Acorda Site #103

    Miami, Florida

  • Acorda Site #133

    Miami, Florida

  • Acorda Site #161

    Naples, Florida

  • Acorda Site #145

    Sunrise, Florida

  • Acorda Site #106

    Tampa, Florida

  • Acorda Site #186

    Atlanta, Georgia

  • Acorda Site #181

    Kailua, Hawaii

  • Acorda Site #171

    Chicago, Illinois

  • Acorda Site #148

    Avon, Indiana

  • Acorda Site #188

    Fort Wayne, Indiana

  • Acorda Site #156

    Franklin, Indiana

  • Acorda Site #146

    Lexington, Kentucky

  • Acorda Site #150

    New Orleans, Louisiana

  • Acorda Site #175

    Fulton, Maryland

  • Acorda Site #136

    Boston, Massachusetts

  • Acorda Site #121

    Boston, Massachusetts

  • Acorda Site #120

    Worcester, Massachusetts

  • Acorda Site #164

    Bingham Farms, Michigan

  • Acorda Site #127

    Detroit, Michigan

  • Acorda Site #123

    East Lansing, Michigan

  • Acorda Site #159

    Grand Rapids, Michigan

  • Acorda Site #101

    Kansas City, Missouri

Showing 40 of 74 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.